Cycloset Patent Expiration

Cycloset is a drug owned by Veroscience Llc. It is protected by 22 US drug patents filed from 2013 to 2024. Out of these, 13 drug patents are active and 9 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 30, 2032. Details of Cycloset's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000522 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US8431155 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US9192576 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US9700555 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US9522117 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US10688094 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US9993474 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US8613947 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US11666567 Bromocriptine formulations
Apr, 2032

(7 years from now)

Active
US9352025 Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(5 years from now)

Active
US9895422 Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(5 years from now)

Active
US10688155 Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(5 years from now)

Active
US8877708 Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
Jun, 2030

(5 years from now)

Active
US8137994 Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Jul, 2023

(1 year, 4 months ago)

Expired
US7888310 Methods of identifying responders to dopamine agonist therapy
Jul, 2023

(1 year, 4 months ago)

Expired
US8137993 Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Jul, 2023

(1 year, 4 months ago)

Expired
US8137992 Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Jul, 2023

(1 year, 4 months ago)

Expired
US5716957 Method for modifying and resetting the bloodstream prolactin levels of a human subject
Feb, 2015

(9 years ago)

Expired
US5679685 Accelerated release composition containing bromocriptine
Oct, 2014

(10 years ago)

Expired
US5756513 Therapeutic process for the treatment of the pathologies of type II diabetes
Nov, 2012

(12 years ago)

Expired
US5468755 Therapeutic process for the treatment of the pathologies of Type II diabetes
Nov, 2012

(12 years ago)

Expired
US5866584 Therapeutic process for the treatment of the pathologies of type II diabetes
Nov, 2012

(12 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cycloset's patents.

Given below is the list of recent legal activities going on the following patents of Cycloset.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 26 Dec, 2023 US10688155
Payment of Maintenance Fee, 4th Year, Large Entity 26 Dec, 2023 US10688094
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2023 US8137993
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2023 US8137994
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2023 US8137992
Payment of Maintenance Fee, 8th Year, Large Entity 24 May, 2023 US9192576
11.5 yr surcharge- late pmt w/in 6 mo, Large Entity 10 Oct, 2022 US7888310
Payment of Maintenance Fee, 12th Year, Large Entity 10 Oct, 2022 US7888310
Maintenance Fee Reminder Mailed 03 Oct, 2022 US7888310
7.5 yr surcharge - late pmt w/in 6 mo, Large Entity 13 May, 2022 US8877708


FDA has granted several exclusivities to Cycloset. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cycloset, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cycloset.

Exclusivity Information

Cycloset holds 1 exclusivities. All of its exclusivities have expired in 2012. Details of Cycloset's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Cycloset is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cycloset's family patents as well as insights into ongoing legal events on those patents.

Cycloset's Family Patents

Cycloset has patent protection in a total of 13 countries. It's US patent count contributes only to 49.0% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Cycloset.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Cycloset's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 30, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Cycloset Generic API suppliers:

Bromocriptine Mesylate is the generic name for the brand Cycloset. 6 different companies have already filed for the generic of Cycloset, with Aurobindo Pharma Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cycloset's generic





About Cycloset

Cycloset is a drug owned by Veroscience Llc. It is used for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. Cycloset uses Bromocriptine Mesylate as an active ingredient. Cycloset was launched by Veroscience in 2009.

Approval Date:

Cycloset was approved by FDA for market use on 05 May, 2009.

Active Ingredient:

Cycloset uses Bromocriptine Mesylate as the active ingredient. Check out other Drugs and Companies using Bromocriptine Mesylate ingredient

Treatment:

Cycloset is used for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.

Dosage:

Cycloset is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.8MG BASE TABLET Prescription ORAL